Xtant Medical Shares Surge 16% Following BioHorizons Deal to Distribute Prolifica in Dental Market
BELGRADE, Montana, August 28, 2026, 14:45. Xtant Medical stock advanced 16% after BioHorizons agreed to introduce the Prolifica line to its dental sales channel, boosting access to the product in the dental sector.
PRODUCT / COMMERCIAL CATALYST
Xtant Medical: dental access versus liquidity
BioHorizons opens a new channel. Contract economics remain private.
Market data: Aug. 28, 2026, 16:15–16:30 EDT
Financials: quarter ended June 30, 2026
Financials: quarter ended June 30, 2026
XTNT close$0.384+16.36%
Volume76.04mshares
Market value$53.9m≈$7.6m added
FY26 sales guide$99–103mreduced outlook
New commercial channel
Xtant: developer, processor and manufacturer. BioHorizons: exclusive U.S./Canada dental and oral-maxillofacial distributor. Brand: Prolifica. Status: available now.
Price, royalties, minimum orders and initial stocking volumes were not disclosed.
Scale bridge
Henry Schein value$10.24bn
Xtant value$53.9m
Scale ratio≈190×
Q2 financial reset
| Metric | Q2 2026 | YoY |
|---|---|---|
| Revenue | $23.0m | −35% |
| Gross margin | 57.9% | −10.7 pts |
| Net result | −$9.4m | vs +$3.6m |
| Adjusted EBITDA | −$2.7m | vs +$6.9m |
Balance-sheet sensitivity
Cash$9.9m
Total debt$23.0m
Revolver room$0.7m
Listed-company comparison
| Company | Price | Day | Market value | Read-through |
|---|---|---|---|---|
| Xtant (XTNT) | $0.384 | +16.36% | $53.9m | Direct product upside |
| Henry Schein (HSIC) | $89.52 | −0.85% | $10.24bn | BioHorizons parent |
| Orthofix (OFIX) | $9.70 | +0.73% | $396.8m | Orthobiologics peer |
| Globus Medical (GMED) | $82.97 | +0.52% | $11.40bn | Device peer |
What would validate the rally
Initial purchase orders; recognized Prolifica revenue; repeat clinician orders; disclosed gross-margin contribution; evidence that dental demand offsets weaker core biologics sales.
Risk monitor
Economics: private terms. Adoption: no volume forecast. Liquidity: debt exceeds cash. Trading: micro-cap volatility and exceptional turnover.
Investor read-through
The BioHorizons partnership can extend Xtant into a new clinical market without duplicating a dental sales network. The $7.6 million equity-value gain is smaller than one quarter of revenue but large beside available liquidity. Investors now need orders and margin data to convert channel access into a cash-flow case.
Sources: Xtant partnership announcement; Xtant Q2 results; StockAnalysis; Google Finance. Historical data and management guidance, not investment advice.
TechStock² Updates
